Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | MMP15 | P51511 | 1/20 | 0.30 |
| ▸ | MMP16 | P51512 | 1/20 | 0.30 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126357 | 0.81 | TRPA1 (0.41) | SLC22A6TDP1FFAR3GPR84SMN1; SMN2 | |
| SCHEMBL49064 | 0.79 | GABRP (0.39) | FFAR3MAPT | |
| SCHEMBL332238 | 0.78 | — | — | |
| SCHEMBL4122966 | 0.74 | — | — | |
| SCHEMBL5172943 | 0.74 | — | — | |
| SCHEMBL9057931 | 0.74 | — | — | |
| SCHEMBL2383532 | 0.73 | — | — | |
| SCHEMBL48787 | 0.73 | — | — | |
| SCHEMBL11577897 | 0.72 | SLC22A6 (0.39) | SLC22A6TDP1SMN1; SMN2MAPT | |
| SCHEMBL15199822 | 0.71 | SLC22A6 (0.35) | SLC22A6TDP1FFAR3GPR84SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116284102-A | Preparation method of silane coupling agent and application of silane coupling agent in polylactic acid composite material | 吉祥三宝高科纺织有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023055427-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | NEW YORK BLOOD CENTER, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-3330252-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3330252-A2 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | Signum Biosciences, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2963012-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20170368011-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9744147-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160361283-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM DERMALOGIX, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9376383-B2 | Isoprenyl compounds | SIGNUM BIOSCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060099417-A1 | Polyurethane-based anhydrous sizing compositions for glass fibres, glass fibres obtained and composite materials comprising said fibres | SAINT-GOBAIN VETROEX FRANCE (FR) | 2006-05-11 | — | — | US | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| EP-0769955-B1 | NON-ANTIGENIC AMINE DERIVED POLYMERS AND POLYMER CONJUGATES | ENZON INC (US) | 2004-03-10 | — | — | EP | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| US-6177087-B1 | ADMINISTERING A POLYMER CONJUGATE | ENZON, INC. | 2001-01-23 | — | — | US | disclosed |
| US-5902588-A | Non-antigenic amine derived polymers and polymer conjugates | ENZON, INC. (US) | 1999-05-11 | — | — | US | disclosed |
| US-5730990-A | Non-antigenic amine derived polymers and polymer conjugates | ENZON, INC. (US) | 1998-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361283-A1 | Isoprenyl Compounds and Methods Thereof | ALOX15B, ALOX15, ALOX5 | SLC22A6 3926/4885TDP1 2255/4885FFAR3 889/4885 |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | ALOX15B, ALOX15, ALOX5 | SLC22A6 3926/4885TDP1 2255/4885FFAR3 889/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | SLC22A6 3844/4885TDP1 1723/4885FFAR3 511/4885 |
| US-20170368011-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | ALOX15B, ALOX15, ALOX5 | SLC22A6 3926/4885TDP1 2255/4885FFAR3 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.